AbbVie: Phase 3 Trial of Atogepant (QULIPTA®) for Preventive Treatment of Episodic Migraine

 

• The Phase 3 ELEVATE study demonstrated atogepant is effective and well-tolerated for the preventive treatment of episodic migraine in people who previously failed two to four classes of conventional oral medications used for prevention
• The trial met its primary and secondary endpoints with results showcasing a significant reduction in mean monthly migraine days for those with episodic migraine taking atogepant 60 mg once daily compared to placebo across a 12-week period
• Data will be presented as part of an oral and poster presentation during the AAN Scientific Platform Session for Emerging Science

https://www.biospace.com/article/releases/abbvie-announces-late-breaking-results-from-phase-3-trial-evaluating-atogepant-qulipta-for-the-preventive-treatment-of-episodic-migraine-among-patients-with-prior-treatment-failure-at-the-2023-aan-annual-meeting/